Calcitonin-salmon is a polypeptide hormone secreted by the parafollicular cells of the ultimobranchial gland of salmon fish. Calcitonin-salmon Nasal Spray is a polypeptide of 32 amino acids manufactured by recombinant DNA technology and is identical to calcitonin produced by salmon fish or chemical synthesis. Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts. Single injections of calcitonin cause a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In vitro studies have shown that calcitonin-salmon causes inhibition of osteoclast function with loss of the ruffled osteoclast border responsible for resorption of bone. Calcitonin-salmon Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Calcimar Approved UseCalcitonin Salmon (synthetic origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. Fracture reduction efficacy has not been demonstrated. Calcitonin Salmon (synthetic origin) Nasal Spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). |
PubMed
Title | Date | PubMed |
---|---|---|
Prevention of heterotopic ossification after total hip replacement: a prospective comparison of indomethacin and salmon calcitonin in 60 patients. | 2001 Oct |
|
Differential effects of amylin and salmon calcitonin on neuropeptide gene expression in the lateral hypothalamic area and the arcuate nucleus of the rat. | 2003 May 1 |
Patents
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 04:01:51 GMT 2023
by
admin
on
Sat Dec 16 04:01:51 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
PHO3A1OI4I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB68992
Created by
admin on Sat Dec 16 04:01:51 GMT 2023 , Edited by admin on Sat Dec 16 04:01:51 GMT 2023
|
PRIMARY | |||
|
100000134934
Created by
admin on Sat Dec 16 04:01:51 GMT 2023 , Edited by admin on Sat Dec 16 04:01:51 GMT 2023
|
PRIMARY | |||
|
1902197-00-5
Created by
admin on Sat Dec 16 04:01:51 GMT 2023 , Edited by admin on Sat Dec 16 04:01:51 GMT 2023
|
PRIMARY | |||
|
PHO3A1OI4I
Created by
admin on Sat Dec 16 04:01:51 GMT 2023 , Edited by admin on Sat Dec 16 04:01:51 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_1 | 1_7 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|